Thales Introduces Imperva for Google Cloud, Bringing Its Enterprise-Grade Application Security Capabilities Directly into Google Cloud
22.4.2026 16:00:00 EEST | Business Wire | Press release
Thales today announced the Controlled Availability of Imperva for Google Cloud, bringing the industry's most trusted application security platform directly into Google Cloud. Designed to operate within Google Cloud, the new offering enables organizations to protect web applications and APIs by leveraging Google Cloud’s Service Extension traffic, preserving existing pipelines, integrations, and monitoring workflows.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422746638/en/
©Thales
As enterprises accelerate cloud adoption, development teams increasingly standardize on native cloud services to improve speed and reduce operational complexity. Many security solutions, however, require external routing that introduces latency and friction. At the same time, native cloud security tools often lack the depth required to protect mission-critical applications at scale, creating friction between development and security teams.
Imperva for Google Cloud is built to resolve that tension
“Organizations shouldn’t have to choose between performance, simplicity, and protection,” said Tim Chang, Global Vice President and General Manager, Imperva Application Security at Thales. “With Imperva for Google Cloud, security is part of the cloud infrastructure, delivering enterprise-grade protection without disrupting how applications are built and delivered.”
Security Built into the Cloud, Not Bolted On
Rather than forcing enterprises to bolt protection on after the fact, Imperva for Google Cloud embeds advanced application security directly into the infrastructure that developers already rely on. By aligning with Google Cloud’s native architecture, Thales enables security that scales with modern application development, supporting faster innovation while maintaining the level of protection required for high-value digital services.
Security Built for Modern Applications
Imperva for Google Cloud integrates directly with Google Cloud Load Balancing using Private Service Connect, allowing traffic to remain within Google Cloud’s network while being inspected and protected.
Key capabilities include:
- Deployment without disruption — No DNS changes, SSL management, or re-architecture required
- Immediate protection with minimal tuning — High-confidence protection from day one, with policies updated daily by a dedicated threat research team
- Resilient architecture — No single point of failure; applications remain available even during disruption
- Automation-first design — API-driven deployment with Terraform support for DevOps workflows
- Reduced operational complexity for DevOps and security teams
A Partnership of Excellence
Thales has a long-standing relationship with Google Cloud and is proud to announce it has won a 2026 Google Cloud Partner of the Year Award in the Infrastructure Modernization: Sovereign Cloud category—recognition that reflects the team’s innovation, commitment to customer success, and impact across the Google Cloud ecosystem. As digital sovereignty becomes a top priority, especially in regulated industries, Thales is collaborating with Google Cloud to advance enterprise data protection across hybrid and multi-cloud environments, helping organizations modernize in the cloud without losing control of their data, operations, or compliance, and enabling customers to scale securely with confidence.
Thales at Google Cloud Next 2026
Thales is excited to participate in Google Cloud Next 2026, taking place at Mandalay Bay in Las Vegas from April 22-24, 2026. Visit us at Booth #4403, where we will be showcasing hands-on demos of:
- Application Security with Imperva for Google Cloud – new solution debut
- External Key Management (EKM) for Google Cloud
- Customer-Managed Encryption Keys for Google Cloud
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion.
The Group allocates €4.5 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies.
Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260422746638/en/
Contacts
PRESS
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom